Aqua Bio Technology ASA-logo

Aqua Bio Technology ASA

Følg pressemeldinger fra Aqua Bio Technology ASA

Registrer deg med din e-postadresse for å få de nyeste sakene fra Aqua Bio Technology ASA på e-post fortløpende. Du kan melde deg av når som helst.

Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

  • Aqua Bio Technology ASA
  • Bygdøy Allé 3
  • 0257 Oslo
Oslo Børs
Vis Alt
År
Vis Alt

Aqua Bio Technology: Board member resignation21.1.2025 10:07:28 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA (the "Company" or "ABT") has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment. For further information, please contact CEO Fredrik William Henriksen phone +47 90 02 00 78. About Aqua Bio Technology ASA ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand. This information is subject to the disclosure requirements in sections 4-2 and 5-12 of the Norwegian Securitie

1 vedlegg

Geir Udnæs new CFO in Aqua Bio Technology6.1.2025 08:45:01 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology has appointed Geir Udnæs as interim CFO. Udnæs is an auditor with a broad and comprehensive career. - We are proud to have a capacity like Geir on the team. For ABT, this is an important part of the ongoing professionalization of the company. As the company has moved from little activity to now being able to show significant growth, it is essential that the team is also strengthened in key positions. An added bonus is that Geir also knows the industry from before, says CEO Fredrik William Henriksen. Udnæs has previously, among other things, been an auditor at Arthur Andersen, CFO at Kistefos, CEO at Midelfart and has extensive experience from corporate services and transactions. - ABT is a very exciting company in an interesting market. I look forward to working with Fredrik and the others in ABT in the future, says Udnæs. For further information, please contact CEO Fredrik William Henriksen phone +47 90 02 00 78. Aqua Bio Technology (ABT) is developing and commerci

1 vedlegg

Geir Udnæs ny CFO i Aqua Bio Technology6.1.2025 08:45:00 CET | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology har utnevnt Geir Udnæs som interim CFO. Udnæs er utdannet revisor med en bred og omfattende karriere. - Vi er stolte av å få med en kapasitet som Geir på laget. For ABT er dette en viktig del i den pågående profesjonaliseringen av selskapet. I takt med at selskapet har beveget seg fra lite aktivitet, til å nå kunne vise betydelig vekst, er det essensielt at laget også styrkes i sentrale posisjoner. En ekstra bonus er at Geir også kjenner til bransjen fra tidligere, sier CEO Fredrik William Henriksen. Udnæs har tidligere blant annet vært revisor i Arthur Andersen, CFO i Kistefos, CEO i Midelfart og med lang erfaring fra finansiell rådgivning og transaksjoner. - ABT er et veldig spennende selskap i et interessant marked. Jeg ser frem til å jobbe med Fredrik og de andre i ABT i tiden som kommer, sier Udnæs. For ytterligere informasjon, vennligst kontakt Fredrik William Henriksen, CEO, telefon +47 90 02 00 78. Aqua Bio Technology (ABT) utvikler og kommersialiserer bærek

1 vedlegg

Aqua Bio Technology ASA – Signed LOI for sale for at least 250 million18.12.2024 09:56:06 CET | Aqua Bio Technology ASA | Inside information

Exclusive agreement linked to the largest retailers in Germany, Austria, Switzerland and the UAE. 3D Innovation Nordic AS ("3D"), a wholly owned subsidiary of Aqua Bio Technology, has entered into an LOI for the sale of Non-food for at least NOK 250 million over 5 years, which is the largest agreement the company has ever entered into. The agreement has been concluded with a major German wholesaler, who will receive 5 years of exclusivity linked to several of 3D's products for the markets in Germany, Austria, Switzerland and the UAE. The agreement that has now been concluded is aimed at the largest retailers in Germany, which means that the potential is significantly greater. - This is a significant and potentially historically large agreement for Aqua Bio Technology. It shows that the strategy of targeted and good acquisitions for distribution is bearing fruit. Furthermore, the potential in the agreement is significantly greater than this. After all, we are talking about an agreement

1 vedlegg

Aqua Bio Technology ASA – Inngått LOI på salg for minst 250 millioner18.12.2024 09:48:01 CET | Aqua Bio Technology ASA | Innsideinformasjon

Eksklusiv avtale knyttet til de største kjedene i Tyskland, Østerrike, Sveits og UAE. 3D Innovation Nordic AS («3D»), et heleid datterselskap av Aqua Bio Technology har inngått LOI på salg av Non-food for minst 250 millioner kroner over 5 år, noe som er den største avtalen selskapet har inngått noensinne. Avtalen er inngått med en større tysk grossist, som får 5 års eksklusivitet knyttet til flere av 3D sine produkter for markedene i Tyskland, Østerrike, Sveits og UAE. Avtalen som nå er inngått er rettet mot flere av de største kjedene i Tyskland, noe som gjør at potensialet er vesentlig større. - Dette er en betydelig og potensielt historisk stor avtale for Aqua Bio Technology. Den viser at strategien om at målrettede og gode oppkjøp for distribusjon bærer frukter. Videre er potensialet i avtalen vesentlig større enn dette. Vi snakker tross alt om en avtale som er på mer enn 10 ganger omsetningen Aqua Bio Technology hadde i hele 2023, sier Fredrik William Henriksen, CEO i Aqua Bio Tec

1 vedlegg

Aqua Bio Technology: Primary Insider Notification5.12.2024 12:53:45 CET | Aqua Bio Technology ASA | Inside information

Aqua Bio Technology ASA ("ABT" or the "Company") has been notified that Terabyte Holding AS has purchased shares in the Company. Please see the attached notification forms for further information. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. This information is subject to the disclosure requirements pursuant to MAR article 19 and section 5-12 of the Norwegian Securities Trading Act. About Aqua Bio Technology ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective, and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part

4 vedlegg

Aqua Bio Technology: Disclosure of large shareholding5.12.2024 08:42:59 CET | Aqua Bio Technology ASA | Major shareholding notifications

Reference is made to the resolution by an extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABT") to increase the Company's share capital with NOK 98,408,672.50 through the issuance of 39,636,469 new shares (the "New Shares"), each at a subscription price of NOK 3.00 and a par value of NOK 2.50. Following the extraordinary general meeting, Pjur Eiendom AS subscribed for 9,066,666 New Shares. Following Pjur Eiendom AS' subscription of the 9,066,666 New Shares, Pjur Eiendom AS holds a total of 11,264,123 shares and votes in the Company, representing approximately 10.35% of the outstanding votes and shares in the Company, and has thereby exceeded both the 5 % and 10 % notifiable thresholds pursuant to section 4-2 of the Norwegian Securities Trading Act. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. About Aqua Bio Technology ASA ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use

1 vedlegg

Aqua Bio Technology: New share capital registered20.11.2024 12:55:57 CET | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 13 November 2024, regarding the resolution from the general meeting in the Company to increase the share capital in the Company through issuance of 39,363,469 new shares, each with a par value of NOK 2.5, with a subscription price of NOK 3.0 per new share (the "New Shares"). The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 272,131,855 divided into 108,852,742 shares, each with a nominal value of NOK 2.50. The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. About Aqua Bio Technology ASA Aqua Bio Technology (ABT) is developing and comm

1 vedlegg

Divestment from Skinteam Norge AS14.11.2024 13:47:20 CET | Aqua Bio Technology ASA | Innsideinformasjon

Aqua Bio Technology ASA (ABT or the Company) has engaged in a series of acquisitions in recent years. Following an analysis of the development milestones and additional investments required for Skinteam Norge AS (Skinteam) to achieve success, positive cash flow, and synergies for the rest of ABT's companies, ABT has decided to cease further funding for Skinteam. Instead, ABT will focus its liquidity on other group entities expected to generate positive cash flow by 2025. Efforts to transition Skinteam to new ownership have not resulted in a viable solution, and based on recent developments, it is anticipated that Skinteam’s board will now decide or accept to wind down operations. The divestment from Skinteam is projected to result in a significant non-cash impairment charge due to the reduction of goodwill on the Group's balance sheet. However, this decision will improve ABT's liquidity and substantially decrease future capital requirements. Following the completion of the recent Priva

1 vedlegg

Aqua Bio Technology ASA – Primary Insider Notifications13.11.2024 18:44:52 CET | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders

Reference is made to the stock exchange notices from Aqua Bio Technology ASA ("ABT" or the "Company") published on 18 October 2024 regarding the successful placement of new shares (the "New Shares") towards the shareholders of Jetcarrier AS and towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange announcement by the Company on 17 October 2024, regarding the entry into of a share purchase agreement (the "Agreement") for the purchase of all outstanding shares in Jetcarrier AS, between the Company (as purchaser) and the shareholders of Jetcarrier AS (as sellers) (the "Acquisition"). In the Acquisition, the consideration shares to be delivered to the sellers were resolved issued in connection with the approval of the Private Placement. In an extraordinary general meeting held on 13 November 2024, the share capital increase in connection with the issuance

7 vedlegg

Aqua Bio Technology: Minutes from extraordinary general meeting – Completion of Private Placement and the Jetcarrier Transaction13.11.2024 13:59:25 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ("ABT" or the "Company") has today held an extraordinary general meeting. All resolutions were made in accordance with the proposals set out in the notice for the extraordinary general meeting which means that the Private Placement and Jetcarrier Transaction announced on 17 October have been completed. The minutes of the extraordinary general meeting are attached to this notice. Following the Jetcarrier Transaction, ABT owns all the shares in Jetcarrier AS which owns 100 % of the shares in Jetcarrier Logistics AS, Isebakkeveien 75 AS, Jetcarrier Solutions AS, Xpanz AS, Norlane AS, Jetcarrier AB, FreightWay AB and Filial Magnoas, and represents a major logistic group in the Nordics. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. About Aqua Bio Technology ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective, and

2 vedlegg

AQUA BIO TECHNOLOGY ASA – SHARE CAPITAL INCREASE REGISTERED12.11.2024 11:46:38 CET | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 29 August 2024, regarding the Company's board of directors' resolution to issue a total of 5,000,000 new shares (the "New Shares") in connection with the settlement of the share component of the purchase price for ABT's acquisition of 3D Innovation Nordic AS. The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 173,723,182.50 divided into 69,489,273 shares, each with a nominal value of NOK 2.50. The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. This information is subject of the disclosure requirements pursuant to section 5-12 of the N

1 vedlegg

Aqua Bio Technology: Update on resolutions for general meeting – Cancellation of Subsequent Offering11.11.2024 23:31:20 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the notice for an extraordinary general meeting in Aqua Bio Technology ASA (the "Company") published on 23 October 2024, and to the private placement of new shares in the Company (the "Private Placement") that was announced placed on 18 October, and to the contemplated subsequent offering of new shares following the Private Placement (the "Subsequent Offering"). The Company's auditor has prepared an independent expert report in connection with the Private Placement, which is attached to this stock exchange notice, and forms part of the decision material for the general meeting. In connection with the Private Placement, the Board has also amended its proposal with respect to the Private Placement where the share capital shall be increased with NOK 98,408,672.50 through issuance of 39,363,469 new shares, i.e. one share less than stated in the notice for the extraordinary general meeting. The reason for the amended proposal is an updated counting of certain receivable

2 vedlegg

Aqua Bio Technology: Notice of extraordinary general meeting - Update on consideration to Jetcarrier sellers23.10.2024 16:59:29 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABT") will be held on 13 November 2024 at 10:00 (CET) at Advokatfirmaet CLP DA, Sommerrogata 13-15, 0255 Oslo. Please find attached the notice to the general meeting. All documents to be treated at the general meeting will be made available at the Company's website www.aquabiotechnology.com - http://www.aquabiotechnology.com. Shareholders who wish to the attend the general meeting is requested to notify the Company as set out in appendix 1 to the notice within 11 November 2024 at 16:00 (CET). In case of attendance by proxy, the proxy form (also included in appendix 1 to the notice) is requested submitted to be received by the Company within the same date. Update on consideration to Jetcarrier sellers As announced on 17 October 2024, the Company has entered into a share purchase agreement with the shareholders of Jetcarrier AS to acquire all outstanding shares in Jetcarrier AS (the "Acquisition"). Further, as

2 vedlegg

Aqua Bio Technology ASA: New CEO appointed22.10.2024 10:15:05 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Oslo, 22 October 2024: Aqua Bio Technology ASA (“ABTEC” or “the Company") is pleased to announce that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. "Håvard Lindstrøm started as CEO in 2021, when ABTEC had less than NOK 2m in revenues. The Board would like to thank Håvard for leading the expansion strategy of ABTEC over the last 3 years and growing the business from 2 small entities to 16 subsidiaries today with a consolidated revenue stream of more than NOK 500m. At the same time, we are very pleased to announce that Fredrik Henriksen has accepted to sign on as our new CEO as the ABT Group is entering a new commercial phase to utilize market potential both in B2B and B2C/D2C channels and value chain optimalization, after a period of acquisitions and impressive expansion" says Jon Olav Ødegård, Chair of the Board of Aqua Bio

1 vedlegg

Correction: Aqua Bio Technology ASA – Private Placement successfully placed18.10.2024 09:38:53 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Correction: The total number of New Shares to be issued was incorrect. Please see updated version below. Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("ABT" or the "Company") published on 17 October 2024 regarding a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange a

1 vedlegg

Aqua Bio Technology ASA – Private Placement successfully placed18.10.2024 08:54:34 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("ABT" or the "Company") published on 17 October 2024 regarding a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange announcement by the Company on 17 October 2024, regarding the entry into of a share purchase agreement for

1 vedlegg

Aqua Bio Technology ASA – Key information relating to the Subsequent Offering18.10.2024 08:53:02 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the announcement by Aqua Bio Technology ASA on 18 October 2024 concerning the successful placement of the conditional private placement with total gross proceeds of approximately NOK 115 million, and a contemplated subsequent offering (the "Subsequent Offering"). Key information for the Subsequent Offering is set out below: Date on which the terms of the Subsequent 17 October 2024 Offering was announced: Last day including right: 17 October 2024 First day excluding right: 18 October 2024 Record date: 21 October 2024 EGM date: On or about 12 November 2024 (to be summoned) Maximum number of new shares: 2,000,000 Subscription price: NOK 3.00 Shall the rights be listed No The issuance of new shares in the Subsequent Offering will be subject to approval of the pertaining share capital increase by the EGM to be held on or about 12 November 2024. The Subsequent Offering is expected to be carried out during the notice period for the EGM, with a one-week subscription period

1 vedlegg

Aqua Bio Technology ASA – Contemplated Private Placement17.10.2024 17:48:42 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Aqua Bio Technology ASA ("ABT" or the "Company") hereby announces a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). The Company further contemplates to carry out a subsequent offering towards eligible shareholders. Reference is also made to the stock exchange announcement by the Company earlier today, 17 October 2024, regarding the entry i

1 vedlegg
  • 1
  • 2
  • 3
  • 4
  • 5
  • Siste
  • >>

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

  • Aqua Bio Technology ASA
  • Bygdøy Allé 3
  • 0257 Oslo
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye